![](https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/07/SciRhom-shutterstock_2394196047-1.jpg)
SciRhom secures $70m for autoimmune diseases treatments
German biopharmaceutical company SciRhom has secured €63m ($70m) in a Series A funding round to expedite the development of iRhom2-targeting therapeutics for autoimmune diseases. The significant financial boost was jointly led by a consortium of investors …